Post-approval follow-up study for the COV001 and COV002 trials to determine the long-term safety and character of immune response to the Oxford-AstraZeneca coronavirus vaccine

| Submission date | Recruitment status No longer recruiting | [X] Prospectively registered | | |
|---------------------------------|--|------------------------------|--|--|
| 31/08/2021 | | [X] Protocol | | |
| Registration date 01/09/2021 | Overall study status Completed | Statistical analysis plan | | |
| | | [X] Results | | |
| Last Edited | Condition category | Individual participant data | | |
| 18/11/2025 | Infections and Infestations | | | |

Plain English summary of protocol

Background and study aims

COVID-19 is a condition caused by the coronavirus (called SARS-CoV-2) that was first identified in late 2019. This virus can infect the respiratory (breathing) system. Some people do not have symptoms but can carry the virus and pass it on to others. People who have developed the condition may develop a fever and/or a continuous cough among other symptoms. This can develop into pneumonia. Pneumonia is a chest infection where the small air pockets of the lungs, called alveoli, fill with liquid and make it more difficult to breathe.

On the 29th December 2020 the UK regulator MHRA authorised the Oxford/AstraZeneca ChAdOx1 nCOV-19 vaccine for emergency use. The first participant received ChAdOx1 nCoV-19 on 23rd April 2020, so there is limited long-term data following human exposure to this new vaccine. Since 2012, several hundred patients have received different ChAdOx-based vaccines to prevent other diseases, including influenza, tuberculosis, prostate cancer and malaria, where to date, no serious adverse events were considered related to those vaccines. Under the "conditions of authorisation for emergency supply" in the UK and other territories, AstraZeneca agreed to meet the demands of a pharmacovigilance risk management plan to provide ongoing monitoring of individuals who have received the vaccine.

This safety and immunogenicity extension study aims partly to fulfil those obligations, while also gathering data to permit investigation into the character and persistence of the immune responses that have been stimulated. As such, this is an observational study, where the researchers do not propose to administer additional medicines. The risk to participants is limited to those resulting from simple blood tests at the two study visits. The findings that result from COV009 will be valuable to vaccine developers and policymakers to inform decisions on future vaccine scheduling and design.

Who can participate?

Participants previously enrolled in the UK Phase I/II (COV001) and Phase II/III (COV002) trials

What does the study involve?

Participants will be assessed at two study visits at 6 and 12 months. Each study visit will consist of a blood draw and collection of information on new adverse events since enrolment.

What are the possible benefits and risks of participating in the study? The participants will have the opportunity to help clinicians better understand the long-term safety of the Oxford/AstraZeneca vaccine. The risks are limited to localised bruising and discomfort can occur at the site of blood sampling. Infrequently fainting may occur. The majority of the blood draws are small volumes.

Where is the study run from? University of Oxford (UK)

When is the study starting and how long is it expected to run for? August 2021 to December 2024

Who is funding the study? AstraZeneca (UK)

Who is the main contact? Nelly Owino, nelly.owino@paediatrics.ox.ac.uk

Contact information

Type(s)

Scientific

Contact name

Prof Andrew Pollard

Contact details

Oxford Vaccine Group
Centre for Clinical Vaccinology and Tropical Medicine (CCVTM)
Churchill Hospital
Old Road
Oxford
United Kingdom
OX3 7LE
+44 (0)1865611400
andrew.pollard@paediatrics.ox.ac.uk

Type(s)

Public

Contact name

Ms Nelly Owino

Contact details

Project Manager Oxford Vaccine Group Department of Paediatrics University of Oxford
Centre for Clinical Vaccinology and Tropical Medicine
Churchill Drive
Oxford
United Kingdom
OX3 7LE
+44 (0)1865611400
nelly.owino@paediatrics.ox.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

2021-003382-36

Integrated Research Application System (IRAS)

300456

ClinicalTrials.gov (NCT)

NCT04324606

Protocol serial number

OVG2021/03, IRAS 300456, CPMS 50168

Study information

Scientific Title

Safety and immunogenicity extension study for ChAdOx1 nCoV-19

Acronym

COV009

Study objectives

This study aims to:

- 1. Document the long-term safety profile of the ChAdOx1 nCoV-19 vaccine
- 2. Evaluate the character and durability of immune responses that are stimulated by the ChAdOx1 nCoV-19 vaccine

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 20/08/2021, South Central - Berkshire Research Ethics Committee (Bristol REC Centre, Temple Quay House, 2 The Square, Temple Quay, Bristol, BS1 6PN, UK; +44 (0)207 104 8372; berkshire.rec@hra.nhs.uk), REC ref: 21/SC/0261

Study design

Multi-centre prospective safety study

Primary study design

Observational

Study type(s)

Prevention

Health condition(s) or problem(s) studied

COVID-19 (SARS-CoV-2 infection)

Interventions

The study aims to enrol participants in parallel with the final visit of their parent trial (COV001 /002), provided they have consented to be contacted for future research.

At consent, participants will have sufficient opportunity to read and understand the contents of the patient information sheet prior to being invited to give informed written consent, with further opportunities to ask questions and seek clarification at the consent and enrolment visit. Participants will be consented to allow the central study team to access their NHS SARS-CoV-2 nucleic acid amplification test (NAAT) results including viral sequencing where it is available from NHS digital and local sequencing labs, using the participants NHS number or other personal identifiers in the event of a diagnosis of COVID-19 during the study period. Consent will also be sought to access all participant's COVID-19 vaccination records through NHS digital or by accessing medical records.

The following data will be collected for any participant that has completed the final study visit for the parent trial on a different day to enrolment in COV009. Any new:

- 1. COVID-19 diagnoses
- 2. Serious adverse events (SAEs)
- 3. Adverse events of special interest (AESI)
- 4. Administration of any vaccines
- 5. Participation in other clinical trials

Participants will be assessed at two study visits after consent and enrolment:

- 1. At 6 months (study visit 1 SV1)
- 2. At 12 months (study visit 2 SV2)

Each study visit will consist of a blood draw for immunology and questions to capture details of any of the following new events since enrolment:

- 1. COVID-19 diagnoses
- 2. Serious adverse events (SAEs) the participant may also be asked about any new medical diagnoses or medically attended adverse events to ensure any SAEs are not missed
- 3. Adverse events of special interest (AESI)
- 4. Administration of any vaccines (any vaccine including but not limited to COVID vaccines are permissible but must be recorded in the eCRF)
- 5. Participation in other clinical trials

In the event that a participant is unable to attend an in-person clinic visit, telephone safety assessments may be conducted instead. Participants will be able to contact the study team outside of study visits 1 and 2 to report any new relevant medical event as stated in the patient information sheet

Following enrolment, some participants (Oxford and Southampton sites only) will be allocated sequentially at enrolment to the exploratory immunology subgroup.

For most participants up to 10 ml of blood will be taken at each of the two visits, totalling 20 ml for the study. For those participants allocated to the 'exploratory immunology' subgroup, a larger volume of blood, up to 50 ml at each visit, will be taken.

Each participant may exercise his or her right to withdraw from the study at any time. In addition, the investigator may terminate a participant's involvement in the study, at any time, if the investigator considers it necessary.

Intervention Type

Biological/Vaccine

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Not provided at time of registration

Primary outcome(s)

Long-term safety of the ChAdOx1 nCoV-19 vaccine measured from the registry of serious adverse events (SAEs) and adverse events of special interest (AESIs) at visit 1 (6 months, +/- 28 days) and visit 2 (12 months, +/- 28 days) and may also be reported by the participant at other times during the study

Key secondary outcome(s))

Character and durability of the immune response to vaccination measured by the immune responses (for a subset of participants, in exploratory immunology group), anti-SARS-CoV-2 spike protein immunoglobulins, and neutralising antibodies against SARS-CoV-2 at visit 1 (6 months +/- 28 days) and visit 2 (12 months +/-28 days)

Completion date

31/12/2024

Eligibility

Key inclusion criteria

- 1. Participated in the COV001 Phase I/II or COV002 Phase II/III trials
- 2. Able and willing to provide written, informed consent to participate in the study
- 3. Able and willing (in the investigator's opinion), to comply with all study requirements
- 4. Consent to general practitioner or responsible physician being notified of participation in the study
- 5. Consent to allow investigators to discuss their medical information with their general practitioner (GP) or responsible physician, and to access any medical records where relevant to the study
- 6. Consent to access NHS SARS-CoV-2 NAAT results, including viral sequencing, results from NHS Digital and local sequencing labs, as well as COVID-19 vaccination records if available

Participant type(s)

Other

Healthy volunteers allowed



Age group

Adult

Sex

Αll

Total final enrolment

1077

Key exclusion criteria

- 1. Participants who have enrolled on a clinical trial of an investigational medicinal product (CTIMP) for a novel COVID-19 vaccine will be excluded. Examples would include the COV-Variant or ComCOV trials
- 2. Participants who fail to enrol onto COV009 within 26 weeks of their last study visit on the parent study will be excluded. If consent is not obtained within 26 days from the last visit on the parent trial, the participant will become ineligible for COV009

Date of first enrolment

01/09/2021

Date of final enrolment

31/08/2022

Locations

Countries of recruitment

United Kingdom

England

Scotland

Wales

Study participating centre

Churchill Hospital

Oxford University, Oxford Vaccine Group

CCVTM

Oxford

England

OX3 7LE

Study participating centre
University Hospital of Southampton
Southampton General Hospital

Tremona Road Southampton England SO16 6YD

Study participating centre St Mary's Hospital

The Bays South Wharf Road London England **W2 1BL**

Study participating centre University Hospital Birmingham

Queen Elizabeth Hospital Mindelsohn Way Edgbaston BIrmingham England **B15 2GW**

Study participating centre St Georges University Hospital

St Georges Hospital Blackshaw Road Tooting London England SW17 0QT

Study participating centre Northern General Hospital

Herries Road Sheffield England **S5 7AU**

Study participating centre St Cadoc's Hospital.

Lodge Road

Caerleon Newport Gwent Wales NP18 3XQ

Study participating centre Northwick Park Hospital

Watford Road Harrow England HA1 3UJ

Study participating centre Southmead Hospital

Southmead Road Bristol England BS10 5NB

Study participating centre University Hospitals Bristol

Marlborough Street Bristol England BS1 3NU

Study participating centre Queens Medical Centre

Derby Road Nottingham England NG7 2UH

Study participating centre Garthnavel Royal Hospital

1055 Great Western Road Glasgow Scotland G12 0XH

Study participating centre Freeman Hospital

High Heaton Newcastle Upon Tyne England NW12PG

Study participating centre Hull Royal Infirmary

Anlaby Road Hull England HU3 2JZ

Study participating centre Cambridge Clinical Research Facility

Cambridge Biomedical Campus Hills Road Cambridge England CB2 0QQ

Study participating centre Lothian NHS Board

Waverleygate 2-4 Waterloo Place Edinburgh Scotland EH1 3EG

Study participating centre St Thomas Hospital

Department of Infection Westminster Bridge Road London England SE1 7EH

Study participating centre

St George's Vaccine Institute

St George's, University of London Cranmer Terrace London England SW17 ORE

Study participating centre Liverpool School of Tropical Medicine (LSTM)

Pembroke Place Liverpool England L3 5QA

Sponsor information

Organisation

University of Oxford

ROR

https://ror.org/052gg0110

Funder(s)

Funder type

Industry

Funder Name

AstraZeneca

Alternative Name(s)

AstraZeneca PLC, Pearl Therapeutics, AZ

Funding Body Type

Government organisation

Funding Body Subtype

For-profit companies (industry)

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available

Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|-------------------------------|-----------------------|--------------|------------|----------------|-----------------|
| Results article | | 16/01/2025 | 18/11/2025 | Yes | No |
| HRA research summary | | | 26/07/2023 | No | No |
| Other unpublished results | Clinical study report | | 18/11/2025 | No | No |
| Participant information sheet | version 4.0 | 18/07/2022 | 19/08/2022 | No | Yes |
| Protocol file | version 2.1 | 24/08/2021 | 31/08/2021 | No | No |
| Protocol file | version 3.0 | 28/10/2021 | 29/11/2021 | No | No |
| Protocol file | version 4.0 | 18/07/2022 | 19/08/2022 | No | No |
| <u>Protocol file</u> | version 4.1 | 18/07/2024 | 07/08/2024 | No | No |